HEIDELBERG, Germany, June 1, 2015 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York. The presentation will take place on Monday, June 1, at 11:30 a.m. EDT at the Grand Hyatt New York, Morosco Room.
About Apogenix
Apogenix is a next generation immuno-oncology company focusing on the development of innovative protein therapeutics for the treatment of cancer and other malignant diseases. With a dedicated, highly qualified team, we have built a promising pipeline of drug candidates that target TNFSF-dependent signaling pathways. Apogenix' TNFSF modulators re-establish the body's immune response against tumors and inhibit invasive tumor cell growth.
Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors and was awarded public grants totaling 8.5 million euros. The company is based in Heidelberg, Germany.
Contact | |
Thomas Hoeger, Ph.D., CEO/CFO | |
Apogenix GmbH | |
Phone: +49 (6221) 58 60 80 | |
E-Mail: contact@apogenix.com | |
Web: www.apogenix.com | |
Media Contacts | |
USA: | Europe: |
Matt Middleman, M.D. | Raimund Gabriel |
Russo Partners, LLC | MC Services AG |
Phone: +1 (212) 845 4272 | Phone: +49 (89) 210 228 30 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apogenix-to-present-at-jefferies-2015-global-healthcare-conference-300091210.html
SOURCE Apogenix
Help employers find you! Check out all the jobs and post your resume.
